|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
HRP20220250T1
(hr)
|
2011-10-03 |
2022-04-29 |
Modernatx, Inc. |
Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
|
|
SI2791160T1
(sl)
|
2011-12-16 |
2022-07-29 |
Modernatx, Inc. |
Sestave modificirane MRNA
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
|
SG10201607962RA
(en)
|
2012-03-27 |
2016-11-29 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
AU2013242404B2
(en)
|
2012-03-27 |
2018-08-30 |
CureVac SE |
Artificial nucleic acid molecules for improved protein or peptide expression
|
|
SG11201405545XA
(en)
|
2012-03-27 |
2014-11-27 |
Curevac Gmbh |
Artificial nucleic acid molecules comprising a 5'top utr
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
AU2013243952A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
SMT202200337T1
(it)
|
2012-11-26 |
2022-09-14 |
Modernatx Inc |
Rna modificato al livello del terminale
|
|
ES2649180T3
(es)
|
2013-02-22 |
2018-01-10 |
Curevac Ag |
Combinación de vacunación e inhibición de la ruta PD-1
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP3461498A1
(en)
|
2013-08-21 |
2019-04-03 |
CureVac AG |
Rabies vaccine
|
|
EP3450561A1
(en)
|
2013-08-21 |
2019-03-06 |
CureVac AG |
Method for increasing expression of rna-encoded proteins
|
|
AU2014310935B2
(en)
|
2013-08-21 |
2019-11-21 |
CureVac SE |
Combination vaccine
|
|
EP4461365A3
(en)
|
2013-08-21 |
2025-02-26 |
CureVac SE |
Respiratory syncytial virus (rsv) vaccine
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
SG10201801428RA
(en)
|
2013-08-21 |
2018-03-28 |
Curevac Ag |
Method for increasing expression of rna-encoded proteins
|
|
MX369469B
(es)
|
2013-08-21 |
2019-11-08 |
Curevac Ag |
Vacuna contra el virus respiratorio sincitial.
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
CA2925021C
(en)
|
2013-11-01 |
2025-05-06 |
Curevac Ag |
MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
EP3415629A1
(en)
*
|
2013-12-30 |
2018-12-19 |
CureVac AG |
Artificial nucleic acid molecules
|
|
EP3842537A1
(en)
|
2013-12-30 |
2021-06-30 |
CureVac AG |
Artificial nucleic acid molecules
|
|
WO2015101415A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
CN111304231A
(zh)
|
2013-12-30 |
2020-06-19 |
库瑞瓦格股份公司 |
人工核酸分子
|
|
SG11201604198YA
(en)
|
2013-12-30 |
2016-07-28 |
Curevac Ag |
Methods for rna analysis
|
|
EP3590529A1
(en)
|
2014-03-12 |
2020-01-08 |
CureVac AG |
Combination of vaccination and ox40 agonists
|
|
EP3129050A2
(en)
|
2014-04-01 |
2017-02-15 |
CureVac AG |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
EP3155129B1
(en)
|
2014-06-10 |
2019-01-16 |
CureVac AG |
Method for enhancing rna production
|
|
IL298516B2
(en)
|
2014-06-25 |
2025-03-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
EP3204399B1
(en)
*
|
2014-10-09 |
2025-01-22 |
Seattle Children's Hospital, dba Seattle Children's Research Institute |
Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
|
|
ES2926020T3
(es)
|
2014-12-12 |
2022-10-21 |
Curevac Ag |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
|
CA2962849A1
(en)
*
|
2014-12-16 |
2016-06-23 |
Curevac Ag |
Ebolavirus and marburgvirus vaccines
|
|
EP3240558A1
(en)
|
2014-12-30 |
2017-11-08 |
CureVac AG |
Artificial nucleic acid molecules
|
|
WO2016165825A1
(en)
|
2015-04-13 |
2016-10-20 |
Curevac Ag |
Method for producing rna compositions
|
|
EP4026568A1
(en)
|
2015-04-17 |
2022-07-13 |
CureVac Real Estate GmbH |
Lyophilization of rna
|
|
JP6912384B2
(ja)
|
2015-04-22 |
2021-08-04 |
キュアバック アーゲー |
癌疾患の処置のための、ｒｎａ含有組成物
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
SG11201708867UA
(en)
|
2015-04-30 |
2017-11-29 |
Curevac Ag |
Immobilized poly(n)polymerase
|
|
WO2016180430A1
(en)
|
2015-05-08 |
2016-11-17 |
Curevac Ag |
Method for producing rna
|
|
AU2016264027A1
(en)
|
2015-05-15 |
2017-08-31 |
Curevac Ag |
Prime-boost regimens involving administration of at least one mRNA construct
|
|
WO2016184575A1
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
US10729654B2
(en)
|
2015-05-20 |
2020-08-04 |
Curevac Ag |
Dry powder composition comprising long-chain RNA
|
|
CN107873055B
(zh)
|
2015-05-29 |
2021-09-17 |
库瑞瓦格房地产有限公司 |
包括至少一个切向流过滤步骤的产生和纯化rna的方法
|
|
US11608513B2
(en)
|
2015-05-29 |
2023-03-21 |
CureVac SE |
Method for adding cap structures to RNA using immobilized enzymes
|
|
SI3313829T1
(sl)
|
2015-06-29 |
2024-09-30 |
Acuitas Therapeutics Inc. |
Lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin
|
|
ES2667644T3
(es)
*
|
2015-06-30 |
2018-05-14 |
Ethris Gmbh |
UTR que aumentan la eficacia de la traducción de las moléculas de ARN
|
|
EP3317424B1
(en)
|
2015-07-01 |
2023-09-06 |
CureVac Manufacturing GmbH |
Method for analysis of an rna molecule
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
EP3325505B1
(en)
*
|
2015-07-23 |
2020-08-19 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
US20200085852A1
(en)
*
|
2015-08-05 |
2020-03-19 |
Curevac Ag |
Epidermal mrna vaccine
|
|
US12258567B2
(en)
*
|
2015-08-28 |
2025-03-25 |
CureVac SE |
Artificial nucleic acid molecules
|
|
CA2998810A1
(en)
|
2015-09-17 |
2017-03-23 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
AU2016340183A1
(en)
|
2015-10-16 |
2018-04-19 |
Modernatx, Inc. |
mRNA cap analogs and methods of mRNA capping
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
DK3362461T3
(da)
|
2015-10-16 |
2022-05-09 |
Modernatx Inc |
Mrna-cap-analoger med modificeret phosphatbinding
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
EP3374504B1
(en)
|
2015-11-09 |
2025-03-19 |
CureVac SE |
Optimized nucleic acid molecules
|
|
US11413346B2
(en)
|
2015-11-09 |
2022-08-16 |
Curevac Ag |
Rotavirus vaccines
|
|
WO2017092808A1
(en)
*
|
2015-12-03 |
2017-06-08 |
Dna Essence Gmbh |
Oligonucleotides in food, beverage, cosmetic and medicinal formulations
|
|
CN108778308A
(zh)
|
2015-12-22 |
2018-11-09 |
库瑞瓦格股份公司 |
生产rna分子组合物的方法
|
|
SMT202200252T1
(it)
|
2015-12-22 |
2022-07-21 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti
|
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
US10626413B2
(en)
|
2016-01-15 |
2020-04-21 |
Enyu Ding |
Nucleic acid vector
|
|
EP4289965A3
(en)
|
2016-02-12 |
2024-02-21 |
CureVac SE |
Method for analyzing rna
|
|
SG10201913630YA
(en)
*
|
2016-02-17 |
2020-03-30 |
Curevac Ag |
Zika virus vaccine
|
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
|
WO2017182634A1
(en)
|
2016-04-22 |
2017-10-26 |
Curevac Ag |
Rna encoding a tumor antigen
|
|
US11596699B2
(en)
|
2016-04-29 |
2023-03-07 |
CureVac SE |
RNA encoding an antibody
|
|
EP4631970A2
(en)
|
2016-05-04 |
2025-10-15 |
CureVac SE |
Nucleic acid molecules and uses thereof
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
EP3468613A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
EP3468608A1
(en)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybrid carriers for nucleic acid cargo
|
|
US20190336608A1
(en)
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN109715205A
(zh)
|
2016-08-19 |
2019-05-03 |
库瑞瓦格股份公司 |
用于癌症治疗的rna
|
|
IL317855A
(en)
|
2016-10-26 |
2025-02-01 |
Acuitas Therapeutics Inc |
mRNA vaccines with lipid nanoparticles
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US11279923B2
(en)
|
2016-11-28 |
2022-03-22 |
Curevac Ag |
Method for purifying RNA
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
JP2020501545A
(ja)
*
|
2016-12-08 |
2020-01-23 |
キュアバック アーゲー |
肝疾患の処置または予防のためのｒｎａ
|
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
CN110381994B
(zh)
|
2017-01-11 |
2024-05-10 |
宾夕法尼亚大学理事会 |
用于诱导针对寨卡病毒的免疫应答的核苷修饰的rna
|
|
CN108456669B
(zh)
*
|
2017-02-20 |
2023-08-08 |
上海凯赛生物技术股份有限公司 |
一种核糖体结合位点、重组表达质粒、转化子及其应用
|
|
AU2018234828A1
(en)
|
2017-03-15 |
2019-09-19 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
EP3596041B1
(en)
|
2017-03-15 |
2022-11-02 |
ModernaTX, Inc. |
Compound and compositions for intracellular delivery of therapeutic agents
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
WO2018172556A1
(en)
*
|
2017-03-24 |
2018-09-27 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
WO2018211038A1
(en)
|
2017-05-17 |
2018-11-22 |
Curevac Ag |
Method for determining at least one quality parameter of an rna sample
|
|
WO2018232120A1
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3642345A1
(en)
*
|
2017-06-20 |
2020-04-29 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Codon-optimized human npc1 genes for the treatment of niemann-pick type c1 deficiency and related conditions
|
|
AU2018298422B2
(en)
|
2017-07-04 |
2023-04-06 |
CureVac SE |
Novel nucleic acid molecules
|
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
|
US12065396B2
(en)
|
2017-08-17 |
2024-08-20 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
WO2019036638A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR PREPARING MODIFIED RNA
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
US11744801B2
(en)
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
IL321714A
(en)
*
|
2017-10-19 |
2025-08-01 |
CureVac SE |
Novel artificial nucleic acid molecules
|
|
EP3707271A1
(en)
|
2017-11-08 |
2020-09-16 |
CureVac AG |
Rna sequence adaptation
|
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
|
EP3728634A1
(en)
|
2017-12-21 |
2020-10-28 |
CureVac AG |
Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
|
|
SG11202009452WA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
JP2021519581A
(ja)
|
2018-04-03 |
2021-08-12 |
ストライドバイオ，インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
JP7425738B2
(ja)
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
BR112020020933A2
(pt)
|
2018-04-17 |
2021-04-06 |
Curevac Ag |
Moléculas de rna de rsv inovadoras e composições para vacinação
|
|
WO2020002525A1
(en)
|
2018-06-27 |
2020-01-02 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
|
JP7352581B2
(ja)
|
2018-06-28 |
2023-09-28 |
キュアバック アールエヌエイ プリンター ゲーエムベーハー |
Ｒｎａインビトロ転写用バイオリアクター
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B1
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
US20220040281A1
(en)
|
2018-12-21 |
2022-02-10 |
Curevac Ag |
Rna for malaria vaccines
|
|
CA3122645A1
(en)
|
2018-12-21 |
2020-06-25 |
Curevac Ag |
Methods for rna analysis
|
|
AU2020214425A1
(en)
|
2019-01-31 |
2021-08-19 |
Modernatx, Inc. |
Vortex mixers and associated methods, systems, and apparatuses thereof
|
|
WO2020160397A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
|
AU2020241888A1
(en)
|
2019-03-21 |
2021-09-30 |
Ginkgo Bioworks, Inc. |
Recombinant adeno-associated virus vectors
|
|
CN109971786B
(zh)
*
|
2019-04-19 |
2022-09-23 |
上海市东方医院（同济大学附属东方医院） |
核孔蛋白Nup54及其载体和重组腺病毒的用途
|
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
|
CN112190591B
(zh)
*
|
2019-07-08 |
2021-12-17 |
中国农业科学院兰州兽医研究所 |
核糖体蛋白rpl13抑制剂在制备抑制ires-依赖性翻译的病毒复制的药物中的应用
|
|
CN111041099B
(zh)
*
|
2019-07-22 |
2021-09-17 |
江苏医药职业学院 |
检测g蛋白偶联受体137b表达水平的试剂的应用和试剂盒
|
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
KR20220083714A
(ko)
|
2019-10-17 |
2022-06-20 |
스트라이드바이오 인코포레이티드 |
니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
|
|
EP4047084A4
(en)
|
2019-10-17 |
2024-01-17 |
Public University Corporation Nagoya City University |
ARTIFICIALLY SYNTHESIZED MRNA AND ITS USE
|
|
CN112980877A
(zh)
*
|
2019-12-12 |
2021-06-18 |
中国科学院大连化学物理研究所 |
一种提高外源基因表达效率的方法
|
|
EP4076647A1
(en)
|
2019-12-20 |
2022-10-26 |
CureVac AG |
Lipid nanoparticles for delivery of nucleic acids
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
EP3886897A1
(en)
|
2020-02-04 |
2021-10-06 |
CureVac AG |
Coronavirus vaccine
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
EP3865579A1
(en)
*
|
2020-02-12 |
2021-08-18 |
Pantherna Therapeutics GmbH |
Recombinant nucleic acid construct and use thereof
|
|
EP4103720A2
(en)
*
|
2020-02-11 |
2022-12-21 |
Pantherna Therapeutics GmbH |
Recombinant nucleic acid construct and use thereof
|
|
CN111218458B
(zh)
*
|
2020-02-27 |
2020-11-20 |
珠海丽凡达生物技术有限公司 |
编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法
|
|
CN111118018B
(zh)
*
|
2020-03-05 |
2021-06-01 |
泰州博莱得利生物科技有限公司 |
猫血清白蛋白重组蛋白及其在毕赤酵母中的表达方法
|
|
IL297084A
(en)
|
2020-04-09 |
2022-12-01 |
Suzhou Abogen Biosciences Co Ltd |
Lipid nanoparticle compounds
|
|
CN113874507A
(zh)
|
2020-04-09 |
2021-12-31 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
JP2023530229A
(ja)
|
2020-05-29 |
2023-07-14 |
キュアバック エスイー |
核酸ベースの混合ワクチン
|
|
US20220331414A1
(en)
|
2020-06-30 |
2022-10-20 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
CA3189338A1
(en)
|
2020-07-16 |
2022-01-20 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
|
AR123288A1
(es)
|
2020-08-19 |
2022-11-16 |
Stridebio Inc |
Vectores de virus adenoasociados para el tratamiento del síndrome de rett
|
|
CN114391008B
(zh)
|
2020-08-20 |
2024-05-03 |
苏州艾博生物科技有限公司 |
脂质化合物和脂质纳米颗粒组合物
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
WO2022066757A1
(en)
*
|
2020-09-23 |
2022-03-31 |
Myeloid Therapeutics, Inc. |
Improved methods and compositions for expression of nucleic acids in cells
|
|
AU2021360494A1
(en)
|
2020-10-14 |
2023-05-18 |
George Mason Research Foundation, Inc. |
Ionizable lipids and methods of manufacture and use thereof
|
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
US11918643B2
(en)
|
2020-12-22 |
2024-03-05 |
CureVac SE |
RNA vaccine against SARS-CoV-2 variants
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
CN112662673B
(zh)
*
|
2021-01-08 |
2022-06-28 |
石河子大学 |
一种人klf7基因启动子及其构建方法与应用
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
CN116615472A
(zh)
|
2021-01-14 |
2023-08-18 |
苏州艾博生物科技有限公司 |
聚合物缀合的脂质化合物和脂质纳米颗粒组合物
|
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
WO2022200575A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
|
US20250345524A1
(en)
|
2021-03-31 |
2025-11-13 |
CureVac SE |
Syringes containing pharmaceutical compositions comprising rna
|
|
CN113174427B
(zh)
*
|
2021-04-29 |
2023-02-28 |
遵义医科大学 |
基于DNA分子检测ERGIC3 mRNA的方法
|
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
|
CA3211623A1
(en)
|
2021-05-24 |
2022-12-01 |
Bo YING |
Lipid compounds and lipid nanoparticle compositions
|
|
AU2022284878A1
(en)
|
2021-06-04 |
2024-01-18 |
Translate Bio, Inc. |
Assay for quantitative assessment of mrna capping efficiency
|
|
CN113801213B
(zh)
*
|
2021-06-23 |
2022-04-08 |
广东省农业科学院水稻研究所 |
一种拟禾本科根结线虫转录因子MgBTF3及其防治病害的应用
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
JP2024534120A
(ja)
|
2021-08-24 |
2024-09-18 |
ビオンテック・ソシエタス・エウロパエア |
インビトロ転写技術
|
|
US20240398933A1
(en)
|
2021-09-03 |
2024-12-05 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
CA3230031A1
(en)
|
2021-09-03 |
2023-03-09 |
Patrick Baumhof |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
EP4402121A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
JP2024536406A
(ja)
|
2021-10-08 |
2024-10-04 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質化合物及び脂質ナノ粒子組成物
|
|
KR20230083893A
(ko)
*
|
2021-12-03 |
2023-06-12 |
고려대학교 산학협력단 |
번역 효율이 향상된 5'-utr, 이를 포함하는 합성 핵산 분자 및 이를 포함하는 백신 또는 치료제 조성물
|
|
CN118434870A
(zh)
*
|
2021-12-13 |
2024-08-02 |
Sml Biopharm株式会社 |
提高表达效率的核酸表达平台
|
|
WO2023114943A2
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
EP4424670A1
(en)
|
2021-12-23 |
2024-09-04 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
EP4460334A1
(en)
*
|
2022-01-07 |
2024-11-13 |
Precision BioSciences, Inc. |
Optimized polynucleotides for protein expression
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
US20250099614A1
(en)
|
2022-01-28 |
2025-03-27 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
CN114645029B
(zh)
*
|
2022-03-11 |
2024-09-10 |
上海交通大学 |
分离人工合成的MpgS蛋白质多肽和MpgP蛋白质多肽及其应用
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
EP4531902A1
(en)
|
2022-05-25 |
2025-04-09 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
CN115845043B
(zh)
*
|
2022-07-20 |
2025-07-29 |
安徽智飞龙科马生物制药有限公司 |
一种模板DNA分子及其在制备mRNA和疫苗中的应用
|
|
WO2024037578A1
(en)
|
2022-08-18 |
2024-02-22 |
Suzhou Abogen Biosciences Co., Ltd. |
Composition of lipid nanoparticles
|
|
CA3267272A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
FLU VIRUS VACCINES
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
TWI888970B
(zh)
|
2022-10-27 |
2025-07-01 |
美商輝瑞大藥廠 |
Rna分子
|
|
DE202023106198U1
(de)
|
2022-10-28 |
2024-03-21 |
CureVac SE |
Impfstoff auf Nukleinsäurebasis
|
|
EP4636090A1
(en)
*
|
2022-12-16 |
2025-10-22 |
Shenzhen Shenxin Biotechnology Co., Ltd. |
Utr for improving translation efficiency and/or stability of rna molecule and use thereof
|
|
TW202435900A
(zh)
|
2023-01-31 |
2024-09-16 |
日商新博基股份有限公司 |
用於增強蛋白質表現之人工合成核酸
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
DE112024001143T5
(de)
|
2023-03-08 |
2025-12-18 |
CureVac SE |
Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
|
|
AU2024234874A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2024192291A1
(en)
|
2023-03-15 |
2024-09-19 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
CN121001738A
(zh)
|
2023-04-27 |
2025-11-21 |
葛兰素史克生物有限公司 |
流感病毒疫苗
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
WO2024248527A1
(en)
*
|
2023-06-01 |
2024-12-05 |
Green Cross Corporation |
5'-utr containing mrna constructs with improved translation efficiency and vaccine compositions comprising same
|
|
WO2024260570A1
(en)
|
2023-06-23 |
2024-12-26 |
CureVac SE |
Nucleic acid encoded antibodies
|
|
WO2025027492A1
(en)
|
2023-07-31 |
2025-02-06 |
Pfizer Inc. |
Coronavirus antigen variants
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025126019A1
(en)
|
2023-12-13 |
2025-06-19 |
Pfizer Inc. |
Rna molecules
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2025134046A1
(en)
|
2023-12-22 |
2025-06-26 |
Pfizer Inc. |
Methods and vaccine compositions for lyme disease
|
|
CN117517657B
(zh)
*
|
2024-01-08 |
2024-04-09 |
中国农业科学院北京畜牧兽医研究所 |
Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
CN119287031B
(zh)
*
|
2024-11-15 |
2025-09-23 |
湖北省农业科学院畜牧兽医研究所 |
Slc25a38基因中与蛋鸡蛋品质性状相关的单倍型snp分子标记组合、引物对及其应用
|